# Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

> **NCT05623410** · PHASE3 · UNKNOWN · sponsor: **ATGC Co., Ltd.** · enrollment: 300 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** ATGC-110
- **BIOLOGICAL:** Xeomin®

## Key facts

- **NCT ID:** NCT05623410
- **Lead sponsor:** ATGC Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-11
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-06-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623410, "Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05623410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*